Name
GS3-01A - EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting
Date & Time
Tuesday, December 6, 2022
Speakers
Virtual Session Link